Cite
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
MLA
Hui, Lucy, et al. “Cost-Effectiveness Analysis of Consolidation with Brentuximab Vedotin for High-Risk Hodgkin Lymphoma after Autologous Stem Cell Transplantation.” Cancer (0008543X), vol. 123, no. 19, Oct. 2017, pp. 3763–71. EBSCOhost, https://doi.org/10.1002/cncr.30818.
APA
Hui, L., von Keudell, G., Wang, R., Zeidan, A. M., Gore, S. D., Ma, X., Davidoff, A. J., & Huntington, S. F. (2017). Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer (0008543X), 123(19), 3763–3771. https://doi.org/10.1002/cncr.30818
Chicago
Hui, Lucy, Gottfried von Keudell, Rong Wang, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff, and Scott F. Huntington. 2017. “Cost-Effectiveness Analysis of Consolidation with Brentuximab Vedotin for High-Risk Hodgkin Lymphoma after Autologous Stem Cell Transplantation.” Cancer (0008543X) 123 (19): 3763–71. doi:10.1002/cncr.30818.